Phase III Study of AK112 for NSCLC Patients (NCT06396065)
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
🩺 Plain-English Summary (8th-Grade Level)
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
Who can join: Review the eligibility criteria below.
Location: CBCC Global Research — Bakersfield, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (74 Sites)
Showing the first 25 of 74 sites.
- CBCC Global Research — Bakersfield, California
- UC San Diego — La Jolla, California
- University of Southern California — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- UCLA Department of Medicine - Hematology/Oncology — Los Angeles, California
- Palo Alto Medical Foundation Research Institute — Mountain View, California
- Providence St. Joseph — Orange, California
- UC Irvine — Orange, California
- Sutter Cancer center — Sacramento, California
- UC DAVIS Comprehensive Cancer Center — Sacramento, California
- Sharp Memorial Hospital — San Diego, California
- California Pacific Medical Center — San Francisco, California
- Providence Medical Foundation — Santa Rosa, California
- Presbyterian Intercommunity Hospital — Whittier, California
- Rocky Mountain Cancer Center — Lone Tree, Colorado
- The Oncology Institute of Hope & Innovation — Fort Lauderdale, Florida
- University of Miami — Miami, Florida
- Florida Cancer Associates - Ocala Oncology — Ocala, Florida
- BRCR Global — Plantation, Florida
- Florida Cancer Specialists - North — St. Petersburg, Florida
- BRCR Global — Tamarac, Florida
- Florida Cancer Specialists -East — West Palm Beach, Florida
- Hematology/Oncology Clinic - SCRI — Baton Rouge, Louisiana
- New England Cancer Specialists — Scarborough, Maine
- American Oncology Partners — Bethesda, Maryland
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Squamous Non-small Cell Lung Cancer
- A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer — Chandler, Arizona
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC — Mobile, Alabama
Explore by condition: All Non-Squamous Non-small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.